

# Immunology in Medicine

A Comprehensive Guide to Clinical Immunology

*Second Edition*

---

Edited by

E. J. HOLBOROW

W. G. REEVES

# Immunology in Medicine

A Comprehensive Guide to Clinical Immunology

*Second Edition*

---

Edited by

**E. J. HOLBOROW**

*Bone and Joint Research Unit,  
The London Hospital Medical College,  
London*

**W. G. REEVES**

*Immunology Department,  
University Hospital,  
Nottingham*



1983

**GRUNE & STRATTON**

*A Subsidiary of Harcourt Brace Jovanovich, Publishers*

London New York

Paris San Diego San Francisco São Paulo

Sydney Tokyo Toronto

GRUNE & STRATTON LTD  
24/28 Oval Road, London NW1 7DX

*United States edition published by*  
GRUNE & STRATTON INC.  
111 Fifth Avenue, New York, New York 10003

Copyright © 1983 by  
GRUNE & STRATTON LTD

*All rights reserved*

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the publisher.

*British Library Cataloguing in Publication Data*

Holborow, E. J.  
Immunology in Medicine.—2nd ed.  
I. Immunology  
1. Title II. Reeves, W. G.  
616.07'9 QR181

ISBN 0-8089-1573-8

LCCN 76-016974

Typeset by Northumberland Press Ltd, Gateshead  
Printed in Great Britain by Fletcher and Sons Ltd, Norwich

## Contributors

---

- B. R. ALLEN, Consultant Dermatologist, *Department of Dermatology, University Hospital, Nottingham, NG7 2UH, England*
- H. E. AMOS, Medical Adviser, *Medical Department, I.C.I. Pharmaceutical Division, Alderley Park, Macclesfield, Cheshire, England*
- P. C. L. BEVERLEY, Senior Scientist, *ICRF Human Tumour Immunology Group, University College London, Faculty of Clinical Sciences, University Street, London, WC1E 6JJ, England*
- D. L. BROWN, Consultant Immunologist, *Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, England*
- J. S. CAMERON, Professor of Renal Medicine, *Department of Medicine, Guy's Hospital, London Bridge, London SE1 9RT, England*
- D. A. S. COMPSTON, Consultant Neurologist, *University Hospital of Wales, Heath Park, Cardiff, CF4 4XW*
- H. L. F. CURREY, Professor of Rheumatology and Head, *Bone and Joint Research Unit, ARC Building, London Hospital Medical College, London E1 2AD, England*
- R. L. DAWKINS, Head, *Department of Clinical Immunology, Royal Perth Hospital, Box X2213 GPO, Perth, Western Australia 6001*
- A. M. DENMAN, Consultant Physician, *Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, England*
- HEATHER M. DICK, Consultant in Clinical Immunology, *Glasgow Royal Infirmary, Castle Street, Glasgow, C4, Scotland*
- D. C. DUMONDE, Professor of Immunology, *Department of Immunology, St Thomas's Hospital and Medical School, Lambeth Palace Road, London SE1 7EH, England*
- W. PAGE FAULK, Professor of Immunology, *Department of Immunology, INSERM U210, Faculty of Medicine, University of Nice, Avenue de Vallombrose, 06034 Nice, France*
- H. FOX, Professor of Reproductive Pathology, *Department of Pathology, Stopford Building, University of Manchester, M13 9PT, England*
- R. C. GODFREY, Consultant Physician, *Western Hospital, Southampton, SO9 4WQ, England*
- J. A. HABESHAW, Consultant Physician, *Medical Oncology Unit, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, England*
- ANNE S. HAMBLIN, Lecturer, *Department of Immunology, St Thomas's Hospital and Medical School, Lambeth Palace Road, London SE1 7EH, England*
- E. J. HOLBOROW, Professor of Immunopathology and Head of Medical Research Council Immunology Group, *Bone and Joint Research Unit, The London Hospital Medical College, Turner Street, London E1 2AD, England*
- S. T. HOLGATE, Senior Lecturer and Honorary Consultant in Medicine, *D Level, Centre Block, Southampton General Hospital, Tremona Road, Southampton, Hants, England*
- D. P. JEWELL, Consultant Physician, *Gastroenterology Unit, The Radcliffe Infirmary, Oxford, England*
- M. PAPAMICHAIL, Director of Immunobiology Department, *Papanicolaou Research Center, Hellenic Anticancer Institute, 171 Alexandras Avenue, Athens 603, Greece*
- R. H. PERSELLIN, Rheumatology Consultant, *Metropolitan General Hospital, San Antonio, Texas, U.S.A.*
- R. J. POWELL, Consultant Immunologist and Senior Lecturer, *Department of Immunology, Queen's Medical Centre, Nottingham, NG7 2UH, England*



vi Contributors

- W. G. REEVES, Consultant Immunologist and Senior Lecturer, *Department of Immunology, Queen's Medical Centre, Nottingham, NG7 2UH, England*
- G. A. W. ROOK, Senior Lecturer and Honorary Consultant, *Department of Bacteriology, Middlesex Hospital Medical School, Riding House Street, London W1, England*
- I. J. RUSSELL, Assistant Professor of Medicine, *Division of Clinical Immunology, Department of Medicine, The University of Texas Health Sciences Center, San Antonio, Texas, U.S.A.*
- A. J. SWANNELL, Consultant in Rheumatology and Rehabilitation, *City Hospital, Hucknall Road, Nottingham, England*
- H. C. THOMAS, Wellcome Senior Research Fellow in Clinical Sciences, Honorary Senior Lecturer and Consultant Physician, *Department of Medicine, Royal Free Hospital and Medical School, London N.W.3, England*
- R. A. THOMPSON, Consultant Immunologist and Director, *Regional Department of Immunology, East Birmingham Hospital, Bordesley Green East, Birmingham, B9 5ST, England*
- A. TING, Principal Scientific Officer, *Nuffield Department of Surgery, The John Radcliffe Hospital, Oxford, England*
- M. W. TURNER, Reader in Immunochemistry, *Department of Immunology, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, England*
- A. D. B. WEBSTER, Consultant Physician, *Division of Immunological Medicine, Clinical Research Centre, Watford Road, Harrow, Middlesex, HA1 3UO, England*
- J. T. WHICHER, Consultant Chemical Pathologist, *Department of Chemical Pathology, Bristol Royal Infirmary, Bristol, BS2 8HW, England*
- SENGA WHITTINGHAM, Serologist, *Clinical Research Unit, The Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Victoria 3050, Australia*
- P. C. WILKINSON, Titular Professor, *Department of Bacteriology and Immunology, University of Glasgow (Western Infirmary), Glasgow G11 6NT, Scotland.*
- D. GWYN WILLIAMS, Senior Lecturer in Medicine and Consultant Nephrologist, *Clinical Science Laboratories, Guy's Tower, Guy's Hospital, London Bridge, London SE1 9RT, England*

## Foreword

---

It is nowadays widely recognized that the activities of the immune system not only protect against microbial invasion and maintain the integrity of higher organisms, but that exaggeration or aberration of these activities can lead to disease. Much of the knowledge on which this recognition is based has been gained only within the last twenty years, and its application in medicine is even more recent. Although concepts in immunology are by no means static, and the mechanisms whereby the immune response is regulated are still far from clear, the use of an immunological approach has produced plausible experimental models of and possible explanations for a wide variety of human disease processes whose pathogenesis was previously obscure. In some instances, the explanations have proved nearly enough correct to guide therapy or even to indicate new therapeutic approaches. In others, the application of immunological techniques has suggested that immunological factors may play a part in production or control of the disease processes but has left their aetiology tantalizingly unsolved, and has revealed *inter alia* that there is still much to learn about fundamental aspects of the immune response, in respect not only of the part played by lymphocytes but also by mononuclear cells, granulocytes and the complement system. In others still, immunological investigations, even when negative, are important for differential diagnosis.

Because the ramifications of immunology are very wide, and the relevant primary information or review articles are scattered throughout many journals, clinicians, pathologists and students badly need critical compilations of existing knowledge. In a rapidly expanding subject, it is difficult to decide when is the right time to make such a compilation, but to my mind, the present is as near to a nodal point as is likely to occur in the foreseeable future. Clinical immunologists, during the last year or two, have reached a fair degree of agreement about what should be their scope and function, and good manuals have been published lately describing most of the basic techniques in their armamentarium. "Immunology in Medicine" sets out to give an account of the relevance of immunological concepts and of information obtained with these techniques in the whole field of clinical practice, using language which is intelligible to the non-specialist and attempting to assess critically the significance of the observations described. Insofar as these have implications for treatment, this is also indicated. The editors and their fellow authors have succeeded in their aim. Because they write from practical experience, the information which they provide has been predigested sufficiently to inform rather than to confuse the reader. Nevertheless, plenty of facts and raw data are included when these are appropriate, backed up by suitable references to the literature. Although this is a multi-author book, the editors have avoided serious overlap or repetition. The volume is large, but so is its subject matter, and it can properly be regarded as a magnum opus.

April, 1977

J H. HUMPHREY M.D., F.R.S.  
Professor of Immunology,  
Royal Postgraduate Medical School,  
Hammersmith Hospital,  
London

## Preface to the First Edition

---

"Immunology in Medicine" is primarily designed for the practising clinician, be he physician, surgeon or pathologist. The large majority of doctors in practice today escaped any specific training in immunology and many find its unfamiliar jargon and growing complexity formidable. Books abound on the more fundamental and specialized aspects, but there is a dearth of texts which communicate the practical importance of immunological developments across the breadth of clinical medicine. Twenty-three of the 34 contributors to this book are actively involved in day-to-day problems of medical care as well as contributing to immunological advances in their own field.

In an initial chapter we have attempted to give an overview of immunology: its history, jargon, cardinal features and mechanisms. The following eight chapters review the important basic aspects and the highlighted keywords in the general index refer back, predominantly, to this section for important definitions. Chapters 10–12 discuss the means by which immunological mechanisms cause disease, with particular emphasis on auto-immune processes in Chapters 11 and 12. Although the basic defect underlying auto-immune reactivity is poorly understood, clinical observation has almost as many clues to offer as have the various animal models which fascinate immunologists.

The traditional *raison d'être* of the immune response—defence against infection—is emphasized in chapters on infective disease and immuno-deficiency. The largest section deals with the immunology of individual system disorders and is followed by contributions on malignancy and transplantation. Although therapy is mentioned wherever relevant, the last two chapters categorize the various means by which untoward immunological responses may be controlled. Apart from improved methods of diagnosis and increasing knowledge of mechanisms, the immunological manipulation of disease processes offers an exciting prospect for the future. Various non-pharmacological manoeuvres have already proved successful and the growth of disease-specific or antigen-specific treatment will add significantly to the skills required of the clinical immunologist in the future.

Guidelines and training programmes are now established for the various personnel necessary for the pursuit of clinical immunology, i.e. physician, pathologist, technologist and non-medical scientist.<sup>1</sup> We hope that this book will prove of value to each of these. Little space has been devoted to the finer details of laboratory technique which is covered by several recent publications.<sup>2,3,4</sup>

The complexities of producing and collating a multi-author work such as this are exponentially related to the number of authors involved. We owe a special debt to our wives and families for their acceptance and support of the role of immunological medicine within the domestic scene.

March, 1977

E. J. HOLBOROW  
W. G. REEVES

1. Reeves, W. G. (1976). Clinical immunology. *Lancet*, 11, 459.
2. Rose, N. R. and Friedman, H. (Eds.) (1976). "Manual of Clinical Immunology". American Society for Microbiology, Washington.
3. Thompson, R. A. (Ed.) (1977). "Techniques in Clinical Immunology". Blackwell Scientific Publications, Oxford.
4. Weir, D. M. (Ed.) (1977). "Handbook of Experimental Immunology". Third edition. Blackwell Scientific Publications, Oxford.

## Preface to the Second Edition

---

Developments in immunology continue to make inroads into the practice of medicine and pathology and considerable changes have taken place since the first edition appeared five and a half years ago. We have continued our aim to communicate the practical importance of advances in immunology across the breadth of clinical medicine and, although the total number of contributors is much as before, we have made various changes in authorship, content and format. Contributors have been encouraged to opt, wherever possible, for a concise and moderately didactic style incorporating key but not exhaustive references.

Although completely revised and largely rewritten, "Immunology in Medicine" is divided into similar sections as before: a general introduction and seven subsequent chapters cover fundamental aspects of the immune system; another five review the role of the immune system in disease; thirteen chapters are devoted to immunological disorders of major body systems or organs; three concentrate on lympho-proliferative and malignant disease and three concluding chapters focus on transplantation and therapeutic aspects of immunology.

Developments in genetic engineering, hybridoma technology and the characterization of various important immunological molecules (e.g. interferons, interleukins, leucotrienes, thymic hormones) in conjunction with advances in immunogenetics, immunoregulation and transplantation all hold promise for therapeutic innovation in the major categories of immunological disorder, i.e. immunodeficiency, allergy, auto-immunity and lympho-proliferative disease.

It is a pleasure to thank Susie McGowan and Emily Wilkinson of Academic Press for the efficient and expeditious way in which they have transformed our manuscripts into the printed word.

March 1983

E. J. HOLBOROW  
W. G. REEVES



# Contents

---

Foreword	vii
Preface to the First Edition	viii
Preface to the Second Edition	ix
1. General Introduction	
W. G. REEVES and E. J. HOLBOROW	
Historical development of immunology	1
The language of immunology	4
The nature of immunological responses	5
Lymphoid and reticuloendothelial systems	6
Immunological mechanisms in disease	9
References	12
I. The Immune System	
2. The Lymphoid System and Lymphocyte Subpopulations	
E. J. HOLBOROW and M. PAPAMICHAIL	
Adaptive immunity	17
The cells of the immune system	19
Cellular interactions in immune responses	21
Lymphocyte surface markers and differentiation antigens	24
References	33
3. Immunoglobulins	
M. W. TURNER	
Structure of human immunoglobulins	36
Biosynthesis, secretion and metabolism of immunoglobulins	46
Biological function of human immunoglobulins	50
References	57
4. Mononuclear Phagocytes and Granulocytes	
P. C. WILKINSON	
The neutrophil	60
The eosinophil	68
The mononuclear phagocyte system	69
Clinical abnormalities of phagocyte function	76
References	78
5. Mast Cells and their Mediators	
S. T. HOLGATE	
Mechanisms of mast cell activation and secretion	80
Preformed inflammatory mediators associated with the mast cell	87
Newly generated mediators	90
Modulation of mast cell associated mediator release	92
References	93

6. Complement	
R. A. THOMPSON	
Definition of complement . . . . .	97
Principle of action . . . . .	97
Activation (priming) pathways . . . . .	99
The classical C3 convertase . . . . .	100
The alternative pathway convertase . . . . .	102
The "attack" mechanism . . . . .	103
Characteristics of C3 and C4 . . . . .	104
Functions of activated C3 . . . . .	106
Biological role of complement . . . . .	108
Involvement of complement in pathological mechanisms . . . . .	108
The role of complement in renal disease . . . . .	110
Inherited or primary complement deficiencies . . . . .	111
Clinical significance of alterations in complement . . . . .	115
References . . . . .	117
7. Lymphokines	
D. C. DUMONDE and ANNE HAMBLIN . . . . .	121
Development of the lymphokine field . . . . .	121
Biological and biochemical characterization of lymphokines . . . . .	127
Role of lymphokines in inflammatory and immunological processes in vivo . . . . .	133
Medical applications of research into lymphokines . . . . .	143
References . . . . .	147
8. Acute Phase Proteins	
R. J. POWELL . . . . .	151
References . . . . .	156

## II. The Role of the Immune System in Disease

9. Immunology of Infectious Disease	
G. A. W. ROOK	
Immunity to bacteria . . . . .	159
Immunity to fungi . . . . .	164
Immunity to protozoa . . . . .	165
Immunity to metazoan parasites . . . . .	168
Immunity to viruses . . . . .	169
Immunization . . . . .	171
Immunodiagnosis . . . . .	173
References . . . . .	176
10. Viruses and Immunopathology . . . . .	179
A. M. DENMAN . . . . .	179
Patterns of virus infection . . . . .	180
Immunopathological mechanisms . . . . .	181
Virus persistence . . . . .	187
Specific examples of antiviral immunity and human disease . . . . .	191
Retroviruses and immunopathology . . . . .	195
Virus-induced auto-immunity . . . . .	196
Novel forms of immunopathology . . . . .	197
Conclusions . . . . .	197
Acknowledgements . . . . .	198
References . . . . .	198
11. Drug Hypersensitivity	
H. E. AMOS	
Drugs acting on the immunological system . . . . .	203

Drugs activating the immunological system . . . . .	205
Investigation of an allergic drug reaction . . . . .	207
Pseudo-allergic reactions . . . . .	209
References . . . . .	211
<b>12. The HLA System and Disease</b>	
HEATHER M. DICK	
The HLA system . . . . .	213
The biochemistry of HLA-antigens . . . . .	216
The HLA system and disease . . . . .	217
References . . . . .	221
<b>13. Immunodeficiency Disease</b>	
A. D. B. WEBSTER	
Defects in antibody production . . . . .	223
Antibody deficiency syndromes . . . . .	224
Treatment of antibody deficiency syndromes . . . . .	229
Selective immunoglobulin deficiencies . . . . .	231
Primary T lymphocyte defects . . . . .	232
Severe combined immunodeficiency . . . . .	233
Miscellaneous syndromes . . . . .	235
Secondary immunodeficiency . . . . .	237
References . . . . .	240
<b>III. System Disorders</b>	
<b>14. The Connective Tissue Diseases</b>	
E. J. HOLBOROW and A. J. SWANNELL	
Rheumatoid arthritis . . . . .	246
Polyarthritis with hypogammaglobulinaemia . . . . .	261
Juvenile chronic polyarthritis . . . . .	261
Systemic lupus erythematosus . . . . .	262
Progressive systemic sclerosis (scleroderma) . . . . .	267
References . . . . .	267
<b>15. Heart Disease</b>	
I. J. RUSSELL and R. H. PERSELLIN . . . . .	273
References . . . . .	283
<b>16. Glomerulonephritis</b>	
J. S. CAMERON and D. GWYN WILLIAMS . . . . .	285
Experimental nephritis . . . . .	287
Human glomerulonephritis . . . . .	289
The mediation of glomerular injury . . . . .	289
Immune complexes in human nephritis . . . . .	293
Special forms of glomerulonephritis . . . . .	295
Immunofluorescent studies in glomerulonephritis . . . . .	305
Immunological tests in the clinical management of patients with glomerulonephritis . . . . .	310
The treatment of glomerulonephritis . . . . .	312
References . . . . .	313
<b>17. Gastro-Intestinal Diseases</b>	
D. P. JEWELL and H. C. THOMAS	
Immunological defence of the gastrointestinal tract . . . . .	317
Pernicious anaemia . . . . .	321
Coeliac disease . . . . .	324

## xiv Contents

Ulcerative colitis and Crohn's disease	327
Alpha chain disease	330
Gastrointestinal allergy	330
References	331
<b>18. Immunological Aspects of Liver Disease</b>	
H. C. THOMAS	
Hepatitis A virus infection	334
Hepatitis B virus infection	334
Hepatitis non-A, non-B virus infection	336
Autoimmune chronic active hepatitis (CAH)	336
Drug-induced chronic active hepatitis	337
Wilson's disease	337
Primary biliary cirrhosis	337
Alcohol-induced liver disease	339
The secondary immunodeficiency of liver disease	339
References	340
<b>19. Disorders of the Reproductive System</b>	343
W. PAGE FAULK and H. FOX	
Immunological aspects of pregnancy	343
Immunological aspects of choriocarcinoma	356
Immunological causes of infertility	357
Immunological aspects of fertility control	360
References	361
<b>20. Immunological Aspects of Diabetes</b>	
W. G. REEVES	
Aetiology and pathogenesis of Type I diabetes	365
Anti-receptor antibody	368
Immune function in diabetes	369
The immune response to insulin	369
Insulin allergy	374
Injection site lipo-atrophy	374
Insulin resistance	375
Vascular complications	375
References	376
<b>21. Disorders of the Thyroid and other Endocrine Glands</b>	
SENGA WHITTINGHAM	
Thyroid autoimmunity	379
Primary hypoparathyroidism	385
Idiopathic hypopituitarism	386
Other disorders	386
Diagnosis	388
Immunopathogenic mechanisms	388
References	390
<b>22. Respiratory Disorders Including Atopy</b>	
R. C. GODFREY	
Definition of atopy	393
Diseases associated with atopy	395
Pathogenesis of asthma	397
Diagnosis and investigation of atopic diseases	398

Treatment of atopic disease . . . . .	400
Immunology of pulmonary infection . . . . .	401
Interstitial lung disease . . . . .	407
General bibliography . . . . .	410
References . . . . .	411
<b>23. Skin Diseases</b>	
<b>B. R. ALLEN and W. G. REEVES</b>	
Structure and function . . . . .	413
Epidermal antigenicity and antibody transport . . . . .	415
Bullous disorders . . . . .	417
Eczema . . . . .	422
Drug eruptions . . . . .	425
Urticaria and angio-oedema . . . . .	426
Cutaneous vasculitis . . . . .	428
Systemic immunological diseases of the skin . . . . .	430
Cutaneous infection . . . . .	431
Photoimmunology . . . . .	434
Miscellaneous disorders . . . . .	435
References . . . . .	437
<b>24. Muscle Disorders</b>	
<b>R. L. DAWKINS</b>	
Structure and function of muscle . . . . .	439
Immunology of muscle . . . . .	443
Experimental disease of muscle . . . . .	443
Polymyositis . . . . .	445
Mixed connective tissue disease . . . . .	451
Sarcoidosis (granulomatous myopathy) . . . . .	453
Myasthenia gravis . . . . .	453
Polymyalgia rheumatica and temporal arteritis . . . . .	463
References . . . . .	464
<b>25. Neurological Disease</b>	
<b>D. A. S. COMPSTON</b>	
Multiple sclerosis . . . . .	467
Acute disseminated encephalomyelitis and isolated demyelinating lesions . . . . .	477
Landry-Guillain-Barré Syndrome . . . . .	478
Subacute sclerosing panencephalitis . . . . .	480
Progressive multifocal leucoencephalopathy . . . . .	482
Ataxia telangiectasia . . . . .	482
Systemic lupus erythematosus . . . . .	483
Polyarteritis nodosa . . . . .	484
Paraproteinaemia and neuropathy . . . . .	484
References . . . . .	485
<b>26. Haematological Disorders</b>	
<b>D. L. BROWN</b>	
Autoimmune haemolytic anaemia (AIHA) . . . . .	487
Drug-induced immune haemolytic anaemia . . . . .	496
Idiopathic thrombocytopenic purpura (ITP) . . . . .	499
Drug-induced immune thrombocytopenia . . . . .	502
Alloimmune neonatal thrombocytopenia . . . . .	503
Alloimmune neonatal neutropenia . . . . .	503
Autoimmune neutropenia . . . . .	503
References . . . . .	504



## IV. Lympho-proliferative and Malignant Disease

27. Lymphomas and Leukaemias	
J. A. HABESHAU	
The tools employed in surface phenotyping	512
Phenotypic features of leukaemia and lymphoma: their relationship to normal cell development	516
Cell phenotypes in lymphoma and leukaemia	520
References	529
28. Monoclonal Proteins	
J. T. WHICHER	
The cellular origins of paraproteins	531
The biochemical characteristics of paraproteins	535
Benign paraproteins	536
Malignant paraproteins	539
The laboratory investigation of paraproteinaemia	548
Complications of paraproteinaemia	553
References	556
29. Malignant Disease	
P. C. L. BEVERLEY	
A brief historical survey	559
T Cell anti-tumour responses	561
Serological approaches to cancer	564
Immunotherapy	568
Conclusion	570
References	570

## V. Therapeutic Aspects

30. Transplantation	
A. TING and HEATHER M. DICK	577
Kidney transplantation	577
Bone marrow transplantation	583
References	586
31. Drugs Affecting the Immune Response	
H. L. F. CURREY	
Immunosuppressive drugs	591
Toxicity of immunosuppressive drugs	595
Drugs stimulating immune responsiveness	599
Clinical practice with drugs which modify immune responses	601
References	606
32. Therapeutic Manipulation of the Immune Response	
W. G. REEVES	
Administration of antigen	613
Administration of antibody	615
Immunological reconstitution	616
Immunopotential	618
Immunosuppression	619
Immunological tolerance and enhancement	621
References	623
Index	627

# General Introduction

W. G. REEVES and E. J. HOLBOROW

---

## HISTORICAL DEVELOPMENT OF IMMUNOLOGY

### Origins in Microbiology

The proposal of the germ theory of infectious disease by Louis Pasteur in 1847 and the confirmation that many important life-threatening diseases were caused by **micro-organisms**, soon led to a search for factors which might protect individuals from the dire consequences of infection (Reid, 1974). Two of the early investigators in this field were Eli Metchnikoff, first in Messina and later in Pasteur's laboratory in Paris, and Paul Ehrlich, working with von Behring and Kitasato in Koch's institute in Berlin.

Metchnikoff became impressed with the ability of migratory cells, present in most multi-cellular organisms, to detect and defend against the invasion of foreign material. On the basis of experiments on **water-fleas** and starfish larvae he propounded a **general theory** which gave pride of place to his wandering "**phagocytes**". Von Behring and Kitasato on the other hand, found that serum taken from animals or patients who had recovered from diphtheria or tetanus was able to confer specific protection when passively transferred to another host. Paul Ehrlich painstakingly continued this work and proposed his "**side-chain**" theory of immunity to explain these biological events. There seemed to be no way of reconciling these two opposing views until Almroth Wright described

the enhancing effect of antibody on phagocytosis in 1903; a process which he called *opsonization*. Although this work shed important light on the process of defence against bacterial infection, his unbridled enthusiasm for "stimulating the phagocytes" led to derision by Bernard Shaw in his play "The Doctor's Dilemma" (1908). In addition to the serum constituents already described by Ehrlich and his colleagues, Jules Bordet discovered in 1899 that a further heat labile serum factor—soon to be known as complement—was necessary for the lysis of infecting micro-organisms.

Detection of the appropriate antibodies in the sera of patients recovering from infectious disease and the elaboration of specific antisera for use in their treatment was followed by a rest phase in the development of immunological knowledge. The general view was that infecting organisms were "bad" and the host response essentially "good". In support of this was work performed almost a hundred years before by the Gloucestershire general practitioner Edward Jenner on the protection against smallpox which could be conferred by inoculating material from cowpox vesicles. His unethical but courageous experiment on an 8-year-old boy—James Phipps—yielded an effective immunological means of controlling and eliminating a disease which had previously affected 60% of the population in the United Kingdom.

Soon after 1900, several lines of evidence began to

suggest that the host response to the ingress of foreign material might not always be favourable and could cause serious harm. While cruising on the Prince of Monaco's yacht, Portier and Richet decided to study the effect of injecting jelly fish extracts into various animals. On their return they experimented with an extract prepared from sea anemone tentacles and made the surprising discovery that dogs which survived a first injection were more severely affected upon subsequent exposure to this antigenic material. This caused these workers to propose the term *anaphylaxis* in contra-distinction to the state of prophylaxis brought about by the use of bacterial antisera. At about the same time, Von Pirquet and Schick working at the Royal and Imperial Paediatric Clinic in Vienna found that "immune antisera" could produce untoward effects. They had cause to inject horse antidipteria serum into a large number of children during an epidemic of the disease and soon found that a condition characterized by fever, urticarial rash, lymphadenopathy, arthritis and proteinuria was liable to ensue approximately 8 days after the injection. This was most commonly seen following a second injection but in a few instances was provoked by the initial treatment. This response gave rise to the term *serum sickness*, a condition now known to be mediated by circulating immune complexes.

Arthus described a similar phenomenon occurring locally in the skin after the repeated injection of foreign serum and Robert Koch became particularly interested in the nature of the host response to tuberculin, describing the phenomenon of delayed hypersensitivity. Although several workers investigated the nature of "bacterial allergy" it was not until 1945 that Landsteiner and Chase demonstrated the importance of cellular responses in the tuberculin reaction and little thought was given to the relative contribution of "seed" and "soil" in the pathogenesis of infectious diseases until relatively recently.

Studies on lymphocytic choriomeningitis (LCM) in mice have provided dramatic evidence of the role of host factors in the production of immunologically mediated tissue damage (Cole *et al.*, 1971). Adult animals inoculated intracerebrally with the virus die from an acute encephalitis within 6-8 days. If inoculation is performed neonatally then the animals do not succumb and become life-long carriers of the virus. A similar effect can be produced by pretreating the adult animal with cyclophosphamide although either form of "carrier state" can be rapidly terminated by the administration of compatible spleen cells from a

normal animal. Studies in man on hepatitis B, various forms of glomerulonephritis and other conditions such as dengue haemorrhagic fever have confirmed the importance of host factors in disease.

### The Recognition of Autoimmunity

Ehrlich and Morgenroth had anticipated the prospect of autoimmune disease in 1901 when they suggested the term "horror autotoxicus" for this possibility. Donath and Landsteiner described the first red cell autoantibody in 1904 but it was not until 1938 that Dameshek and Schwartz rediscovered autoimmune haemolytic anaemia and proposed that autoreactivity might be a more general phenomenon. Various experimental models were developed by Witebsky and others: the commonest means of production being to inject animals with tissue extracts in the presence of Freund's adjuvant. That a number of human diseases are characterized by the presence of autoantibodies was soon established following the development of the technique of immunofluorescence by Coons in 1955. More recently, the story has come full circle with the knowledge that viruses have an important role in the development of several spontaneously occurring autoimmune diseases in animals and possibly in man. This adds a further dimension to the role of host factors in the pathogenesis of infectious disease.

### Immunological Individuality and Transplantation

The existence of genetically determined tissue antigens was first established by Gorer in the 1930s. The further observation was made (Owen, 1945) that dizygotic twin cattle sharing a placenta each possess red cells of both genetic types. It was also shown that these non-identical twin animals would tolerate skin grafts exchanged between them. This led to work by Burnet's group in 1950 and Billingham, Brent and Medawar in 1953 which attempted to discover whether the introduction of "foreign" material before an animal was immunologically mature would result in that material becoming recognized as "self". The latter group found that this was feasible in newborn mice receiving foreign cells and this phenomenon was termed "actively acquired tolerance".

Human organ grafting became a reality in the early 1960s with the advent of renal allo-transplantation. Although elegant animal experiments have suggested the possibility of inducing specific unresponsiveness to foreign antigens, this has not yet proved to be widely applicable as a means of immunosuppression in man.

and transplanted patients still have to be maintained on relatively large doses of non-specifically immunosuppressive drugs. However, some form of "immunological enhancement" may become a practical possibility in the relatively near future (see Chapter 32).

### Protein Chemistry and Antibody Structure

The presence of an unusual protein—now recognized as free antibody light chains—in the urine of a patient with myelomatosis was described as long ago as 1847 (Clamp, 1967). Following the development of plasma protein electrophoresis by Tiselius and Kabat in 1938, antibodies were characterized as  $\gamma$ -globulins and in 1948 Fagraeus demonstrated their synthesis by plasma cells. Porter showed in 1959 that the antigen combining sites of antibody molecules could be chemically separated from the biologically active sites that trigger the various effector systems such as serum complement. Soon after, Edelman discovered that antibody molecules contain four protein subunits—two "heavy" and two "light". These two lines of evidence enabled the asymmetrical four-chain structure of antibody molecules to be elucidated (see Chapter 3).

The development of gel diffusion methods for studying antigen-antibody interactions by Elek, Oudin and Ouchterlony in the late 1940s as well as the application of immunoelectrophoresis by Grabar and Williams in 1953 enabled great strides to be made in the analysis of antibody reactivity.

IgG ( $\gamma$ G) and IgM ( $\beta_2$ M) were soon recognized as different kinds of antibody molecule but it was not until 1961 that Heremans identified IgA ( $\beta_2$ A) as a separate class of antibody synthesized predominantly in the gastrointestinal tract. The recognition of myelomatosis as a condition associated with the neoplastic proliferation of a single clone of antibody-producing plasma cells and the discovery of myeloma proteins that did not type with existing reagents made possible the identification of two further classes of antibody molecule—IgD in 1965 by Rowe and Fahey, and IgE in 1967 by Johansson and Bennich.

### Cellular Immunology

Rudolf Virchow had noted in 1858 that circulating mononuclear cells could be either large or small, and was aware that "the more the glands become enlarged ... the larger and more perfectly developed are the individual colourless cells of the blood wont to be". There was little addition to this state of knowledge until Gowans and his group described

the heterogeneity and recirculation of lymphocytes in the 1960s (Gowans, 1966). Since then study of the cells and tissues of the lymphoid system has been one of the most prolific areas of investigation. Glick and his colleagues described the accidental discovery of the importance of the bursa of Fabricius in antibody production in the chicken in 1956 and Miller drew attention to the key role of the thymus in immunological development in 1961. Cell mediated responses and their clinical counterpart "delayed hypersensitivity" had already been shown to function independently of antibody and in the 1960s it was found that some lymphocytes are capable of synthesizing soluble factors of their own which are responsible for many of the phenomena seen in cellular responses (see Chapter 7). In 1970 the presence of surface immunoglobulin was detected on those lymphocytes (B cells) destined to transform into plasma cells and secrete antibody (Raff, 1976) and many other markers have since been identified for lymphocytes of both T and B lymphocyte series (see Chapters 2, 27 and 29).

Evidence from various immunodeficiency states has given adequate confirmation of the compartmentation of the immune system into T and B cell components although the phenomenon of "co-operation" between these two kinds of lymphocyte is well established. Initially, this was thought only to operate in terms of T cells providing help toward optimal B cell function but evidence now exists for several varieties of suppressor cell (Benacerraf, 1981) and proposals for immunoregulatory circuits abound (Cantor and Gershon, 1979; Herzenberg *et al.*, 1980).

### The Problem of Diversity

Each individual immunological response is remarkably specific in its reactivity but yet there are potentially millions of different responses. The means by which such a wide range of specificity of response could be elaborated within a single multicellular organism has produced various theories. Haurowitz initially proposed an "instructive" theory of antibody formation in which the reactivity and specificity of the resultant antibody was largely determined by the nature of the immunizing antigen: the latter acting as a template for the synthesis of antibody molecules. The rival view that pre-existing clones of cells with their "ready-made" specific receptors are "selected" by antigen still holds sway (Burnet, 1954), although the differential contribution of the various possible sources of variation, i.e. germ-line genes, somatic